Wednesday, August 31, 2016 4:45:44 PM
Either Seymour is lying here, or he was lying to the investing public when he presented that schedule in Jan 2016:
"Since the end of June marks the end of our fiscal year, this is an opportunity to write a CEO letter that addresses these concerns.
Unfortunately, most non-scientists don’t understand the complexity of the outside testing process. This is not like a pathology lab where you send in a sample for analysis, the sample is tested using a standard protocol and the results are sent back quickly. Our staff has the equipment and the knowledge to do this testing but you always want independent analysis. In the future, as we do this multiple times with different drugs, the universities will have developed their own verifiable and reproducible protocols
All of our new hires receive months of training, no matter what their background is. We have to help educate the university scientists.
Our university and commercial collaborators need our help in setting up their testing protocols. They have to run multiple positive and negative controls to verify that their results will be reproducible. Then they run the samples multiple times. An animal protocol has to be developed, tested, verified and then run again looking for consistent results.
Nanotechnology is generally new to these universities, especially working with polymeric nanomicelles. We have 25 years of experience. We also have millions of dollars of specialized testing equipment that lets us do very sophisticated analysis. Unfortunately, the universities don’t have this equipment!
That’s why it's taking so long"
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM